Guardant Health Inc's stock dropped 13.05% this week amid recent developments.
Guardant Health Inc saw a notable decline of 13.05% this week, closing at US$163.97. Over the past week, the stock has declined 2.79% in just one day, while it has gained 3.44% over the last month and is up 60.01% year-to-date. The trading volume this week was 653,489 shares, which is 0.75 times the 20-day average volume of 1,990,582 shares, indicating lower trading activity compared to previous weeks.
Advertisement
Guardant Health Inc
GH.US
GH.US
Guardant Health Inc
WealthAwesomeMarket cap
$21.85B
52W high
$191.05
52W low
$62.99
1W change
-13.05%
Beta
1.58
Analyst Price Targets
Based on 26 analysts covering GH · as of Oct 13, 2026
Wall Street analysts forecast GH stock price to rise 1372.8% over the next 12 months.
Consensus
Strong Buy4.69 / 5.00
Avg. Target
C$201.04
+1372.8% Upside
Previously C$200.44 on Oct 12, 2026
Current Price
C$13.65
Last close
Analyst Breakdown (26 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GH's historical volatility
30-Day Vol
47.4%
Annualized
90-Day Vol
51.6%
Annualized
Trend (90d)
+18.2%
Annualized drift
90d Mean
C$173.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$166.36 | C$141.28 – C$195.91 |
| 60 trading days | C$170.02 | C$134.93 – C$214.23 |
| 90 trading days | C$173.75 | C$130.91 – C$230.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent decline in stock price may reflect investor sentiment following the latest company developments, particularly as the company prepares to report third-quarter financial results.
Guardant Health's Stock Declines 13.05% This Week
With a current market cap of approximately US$21.84 billion, Guardant Health's stock has seen significant fluctuations, reflecting investor concerns and market dynamics.
Bull case
Analysts have set an average target price of US$201.04 for Guardant Health, suggesting a potential upside of 22.6% from the last close. This outlook may attract some investors looking for opportunities.
Bear case
The company is currently facing challenges with a negative profit margin of -38.3% and an alarming return on equity of -4584.5%. These figures may raise concerns about its financial health among investors.
Significant Weekly Decline
Advertisement
This week, Guardant Health's stock experienced a significant decline of 13.05%, closing at US$163.97. This drop is part of a broader market trend, where the stock has seen a 2.79% decrease in the last day. Currently, the stock is trading below its 50-day moving average of US$167.88, reflecting a 2.3% decline, but is above the 200-day moving average of US$126.05, showing a 30.1% increase. The stock's 52-week range is between US$62.99 and US$191.05, indicating it is currently at 79% of its range.
Recent Company Developments
On October 8, Guardant Health announced the approval of its Guardant360® CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™ in Europe. This approval is a significant milestone for the company, potentially increasing its market presence in advanced ER-positive breast cancer diagnostics. Additionally, the company is set to report its third-quarter financial results on November 5, 2026. Investors will be keen to see how these developments impact the company's financial performance and future outlook.
Market Position and Outlook
Guardant Health holds a market capitalization of approximately US$21.84 billion. Despite the recent decline, analysts have an average target price of US$201.04, implying a potential upside of 22.6% from the current price. The company is facing challenges with a profit margin of -38.3% and a return on equity of -4584.5%, which may raise concerns among investors about its financial stability. Investors will be closely watching the upcoming earnings report for insights into the company’s performance and strategic direction.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
